Icon

TRELEGY ELLIPTA (nda209482)- (0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH)

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE GLAXOSMITHKLINE
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH
No No
2031-Apr-11 2018-Dec-18
None None
None No
TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta2-adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). • the maintenance treatment of asthma in patients aged 18 years and older.
0 0 0
Total Other Developers 6
Drugs with Suitability No
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH ** ** Up - -
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.